Gonadal disorder

Summary

Gonadal disorder (MONDO:0002259) is a disease (an umbrella term covering 6 Mondo subtypes) and 11 clinical trials. Top therapeutic interventions include testosterone enanthate, avelumab, and finasteride. A subtype of reproductive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gonadal disorder
Mondo ID	MONDO:0002259
MeSH	D006058
DOID	DOID:2277
NCIT	C26786
UMLS	C0018050
MedGen	9074
Anatomy (UBERON)	UBERON:0000991
Is cancer (heuristic)	no

Also known as: disease of gonad · disease or disorder of gonad · disorder of gonad · disorder of gonads · gonad disease · gonad disease or disorder · gonadal disorder · gonadal disorders

Disease family

This is a subtype of reproductive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › gonadal disorder

Related subtypes (29): pelvic organ prolapse, cortisone reductase deficiency, physiological sexual disorder, female reproductive system disorder, male reproductive system disorder, pituitary gland disorder, infertility disorder, hypospadias, reproductive system neoplasm, dysplasia of cervix, female genital tuberculosis, habitual spontaneous abortion, aromatase excess syndrome, hand-foot-genital syndrome, mullerian duct anomalies-limb anomalies syndrome, Currarino triad, double uterus-hemivagina-renal agenesis syndrome, congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency, congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency, spondylocostal dysostosis-anal and genitourinary malformations syndrome, congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency, hypomyelinating leukodystrophy 8 with or without oligodontia and-or hypogonadotropic hypogonadism, estrogen resistance syndrome, short stature, microcephaly, and endocrine dysfunction, diethylstilbestrol syndrome, sexually transmitted disease, NR5A1-related sex development disorder

Subtypes (6): precocious puberty, disorder of sexual differentiation, hypogonadism, testicular disorder, ovarian disorder, gonadoblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
Not specified	4
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04460872	PHASE2	RECRUITING	Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
NCT00947713	PHASE1/PHASE2	COMPLETED	Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome
NCT02248701	PHASE2	TERMINATED	Testosterone Plus Finasteride Treatment After Spinal Cord Injury
NCT03335254	PHASE1/PHASE2	TERMINATED	A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
NCT03403777	PHASE2	COMPLETED	Avelumab in Refractory Testicular Germ Cell Cancer.
NCT03562897	PHASE2	COMPLETED	Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
NCT04556071	PHASE2	UNKNOWN	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
NCT00202462	Not specified	COMPLETED	The Effect of Testosterone on Mood and Quality of Life
NCT00341458	Not specified	COMPLETED	Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
NCT00392457	Not specified	COMPLETED	Investigating the Regulation of Reproductive Hormones in Adult Men
NCT05048654	Not specified	WITHDRAWN	A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TESTOSTERONE ENANTHATE	4	2
AVELUMAB	4	1
FINASTERIDE	4	1
NIRAPARIB	4	1
TESTOSTERONE UNDECANOATE	4	1
CHEMBL4777013	0	1